全球数位生物标记市场规模、份额、成长分析，按类型、临床实践、治疗领域（心血管和代谢疾病、呼吸系统疾病）、最终用途 - 2024-2031 年产业预测

2022年全球数位生物标记市场规模约29.6亿美元，预计将从2023年的36.1亿美元增至2031年的175.9亿美元，预测期（2024-2031年）复合年增长率为21.9% ） 。

由于与健康相关的行动应用程式和互联数位装置的快速采用，以及智慧型手机使用的日益普及、新型穿戴装置的推出以及治疗领域应用的拓宽，该市场有望扩大。期待已久的批准使患者及其医疗保健提供者能够更深入地了解心臟健康，包括早期发现表明心血管疾病的特定心律不整。因此，数位生物标记市场正在经历大幅成长。此外，在旨在加快数位生物标记研究的金融和投资活动加强的推动下，预计医疗保健产业将在预测期内出现成长。此外，众多健康科技公司贡献了其数位生物标记技术来对抗 COVID-19 大流行，进一步推动市场扩张。 Medopad 与国际合作伙伴之间的合作旨在加快验证过程，识别呼吸指标等关键资料点的数位生物标记，并找出感染 COVID-19 风险较高的个人，从而使市场受益。此外，数位生物标记的范围超出了智慧手錶和活动追踪器。大型製药公司正在与创新的数位健康新创公司合作，加速该技术的采用，并增强数位生物标记领域的新颖解决方案，从而促进市场成长。政府组织认识到 COVID-19 大流行带来的严峻挑战，并表示有兴趣开发基于数位生物标记的药物。儘管数位生物标记物提供了无数优势，但某些障碍，例如对资料隐私、可靠性、资料验证和缺乏开源资料的担忧，预计将阻碍市场成长。然而，在预测期内，日益激烈的竞争和这些系统的扩大利用预计将克服这些挑战。

目录

执行摘要

• 市场概况
• 命运之轮

研究方法论

• 资讯采购
• 二手和主要资料来源
• 市场规模估计
• 市场假设与限制

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战

主要市场洞察

• 技术分析
• 定价分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• 启动分析
• 原料分析
• 创新矩阵
• 管道产品分析
• 总体经济指标
• 顶级投资分析
• 成功的关键因素
• 竞争程度

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战
• 监管环境
• 波特分析
• 对未来颠覆的特别见解

按类型分類的全球数位生物标记市场

• 市场概况
• 穿戴式
• 基于行动的应用程式
• 感应器
• 其他的

按临床实践分類的全球数位生物标记市场

• 市场概况
• 诊断数位生物标记
• 监测数位生物标记
• 预测和预后数位生物标记物
• 其他（安全
• 药效学/反应
• 敏感性）

按治疗领域分類的全球数位生物标记市场

• 市场概况
• 心血管和代谢疾病（CVMD）
• 呼吸系统疾病
• 精神疾病
• 睡眠与运动疾病
• 神经系统疾病
• 肌肉骨骼疾病
• 和其他（糖尿病
• 疼痛管理）

按最终用途分類的全球数位生物标记市场

• 市场概况
• 医疗保健公司
• 医疗保健机构
• 付款人
• 和其他（患者
• 照顾者）

全球数位生物标记市场规模（按地区）

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • MEA 的其余部分

竞争格局

• 前 5 名玩家比较
• 2021 年关键参与者的市场定位
• 主要市场参与者所采取的策略
• 最佳制胜策略
• 近期市集活动
• 主要公司市占率（%），2021年

主要公司简介

• ActiGraph LLC
• AliveCor Inc.
• Koneksa
• Altoida Inc.
• Amgen Inc.
• Biogen Inc.
• Empatica Inc.
• Vivo Sense
• IXICO plc
• Adherium Limited
• Neurotrack Technologies, Inc.
• Aural Analytic
• Huma
• Sonde Health, Inc.
• Clario
• Imagene AI
• Brainomix
• Kinsa Inc.
• Feel Therapeutics
• ResApp (Pfizer)

Global digital biomarkers market size was valued at around USD 2.96 billion in 2022 and is expected to rise from USD 3.61 billion in 2023 to reach a value of USD 17.59 billion by 2031, at a CAGR of 21.9 % over the forecast period (2024-2031).

The market is poised for expansion owing to the rapid adoption of health-related mobile applications and connected digital devices, alongside the increasing prevalence of smartphone usage, the introduction of novel wearables, and the broadening applications in therapeutic domains. The much-awaited approval is empowering patients and their healthcare providers with deeper insights into cardiac health, including the early detection of specific arrhythmias indicative of cardiovascular disease. Consequently, the market for digital biomarkers is experiencing a substantial growth surge. Moreover, the healthcare sector is expected to witness growth over the forecast period, fueled by heightened financial and investment activities aimed at expediting research on digital biomarkers. Additionally, numerous health technology companies have contributed their digital biomarker technologies to combat the COVID-19 pandemic, further driving market expansion. Collaborations, such as that between Medopad and international partners, aim to expedite the validation process, identify digital biomarkers for critical data points like respiratory indicators, and pinpoint individuals at higher risk for COVID-19, thus benefitting the market. Furthermore, the scope of digital biomarkers extends beyond smartwatches and activity trackers. Major pharmaceutical companies are teaming up with innovative digital health start-ups to accelerate the adoption of this technology and enhance novel solutions in the realm of digital biomarkers, thereby fostering market growth. Government organizations, acknowledging the profound challenges posed by the COVID-19 pandemic, are expressing interest in developing medications based on digital biomarkers. Despite the myriad advantages offered by digital biomarkers, certain obstacles, such as concerns regarding data privacy, reliability, data validation, and the absence of open-source data, are anticipated to impede market growth. However, during the forecast period, increasing competition and expanded utilization of these systems are expected to surmount these challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the global digital biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Digital Biomarkers Market Segmental Analysis

The global digital biomarkers market is segmented based on type, clinical practice, therapeutic area, end-use, and region. By type, the market is segmented into wearable, mobile based applications, sensors, and others. By clinical practice, the market is segmented into diagnostic digital biomarkers, monitoring digital biomarkers, predictive, and prognostic digital biomarkers, and others (safety, pharma co-dynamics/ response, susceptibility). By therapeutic areas, the market is segmented into cardiovascular and metabolic disorders (CVMD), respiratory disorders, psychiatric disorders, sleep & movement disease, neurological disorders, musculoskeletal disorders, and others (diabetes, pain management). By end-use, the market is segmented into healthcare companies, healthcare providers, payers, others (patient, caregivers). By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Digital Biomarkers Market

The increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer is fueling the demand for digital biomarkers. These biomarkers play a crucial role in the early detection and management of these conditions.

Restraints in the Global Digital Biomarkers Market

The absence of definitive regulatory guidelines for digital biomarkers is impeding the growth of this market by creating uncertainty for investors and manufacturers alike.

Market Trends of the Global Digital Biomarkers Market

The growing popularity of wearables and mobile health apps among both consumers and healthcare providers is fueling the expansion of the digital biomarkers market. These technologies facilitate continuous and remote monitoring of patients, generating substantial amounts of data that can be leveraged to develop digital biomarkers.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Digital Biomarkers Market by Type

• Market Overview
• Wearable
• Mobile based Applications
• Sensors
• and Others

Global Digital Biomarkers Market by Clinical Practice

• Market Overview
• Diagnostic digital biomarkers
• Monitoring digital biomarkers
• Predictive and Prognostic digital biomarkers
• Other's (Safety
• Pharmacodynamics/ Response
• Susceptibility)

Global Digital Biomarkers Market by Therapeutic Area

• Market Overview
• Cardiovascular and metabolic disorders (CVMD)
• Respiratory disorders
• Psychiatric disorders
• Sleep & Movement Disease
• Neurological disorders
• Musculoskeletal disorders
• and Others (Diabetes
• Pain Management)

Global Digital Biomarkers Market by End-Use

• Market Overview
• Healthcare companies
• Healthcare Providers
• Payers
• and Others (Patient
• caregivers)

Global Digital Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• ActiGraph LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AliveCor Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koneksa
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altoida Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Empatica Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivo Sense
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IXICO plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adherium Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotrack Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aural Analytic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonde Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clario
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imagene AI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Brainomix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kinsa Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Feel Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ResApp (Pfizer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments